Aug 16, 2006 - proglucagon-derived peptides (PGDP) that also includes enteroglucagon, is secreted from L-type entero-endocrine cells of the distal small ...
November 2006
Biol. Pharm. Bull. 29(11) 2327—2330 (2006)
Notes
2327
Correlation between Plasma Glucagon-Like Peptide 2 Levels and Proliferative Makers in Small Intestinal Injury in Rats Induced by Methotrexate Administration Yoshihiko HIROTANI,*,a,b Kaoru YAMAMOTO,b Kenji IKEDA,a,b Yukio ARAKAWA,b,c Jun LI,d Kazuyuki KITAMURA,d Nobuo KUROKAWA,b and Kazuhiko TANAKAe a
Laboratory of Clinical Pharmaceutics, Faculty of Pharmacy, Osaka Ohatani University; 3–11–1 Nishikoorikita, Tondabayashi 584–8540, Japan: b Department of Pharmacy, Osaka University Hospital; 2–15 Yamadaoka, Suita 565–0871, Japan: c Clinical Laboratory of Practical Pharmacy, Osaka University of Pharmacetical Sciences; 4–20–1 Nasahara, Takatuki 569–1094, Japan: d Yanaihara Institute Inc.; 2480–1 Awakura, Fujinomiya 418–0011, Japan: and e Department of Clinical Pharmacy & Clinical Pharmacokinetics, Osaka University of Pharmacetical Sciences; 4–20–1 Nasahara, Takatuki 569–1094, Japan. Received June 20, 2006; accepted August 14, 2006; published online August 16, 2006 Glucagon-like peptide 2 (GLP-2) is a potent intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. We examined whether a relationship exists between plasma level of GLP-2 and the degree of intestinal injury induced by chemotherapeutic agents in the rat. Methotrexate (MTX) was administrated orally for 6 consecutive days at doses of 1.25, 2.5, and 5.0 mg/kg body weight per day. Mucosal samples of rat duodenum, jejunum, and ileum were used for assessment of mucosal weight, DNA and protein content. Plasma GLP-2 levels were measured on day 8. MTX significantly reduced body weight. The values of all indices tended to decrease in all segments with increases in MTX dose. Plasma GLP-2 levels were significantly higher in the MTX 2.5 mg/kg/d group (p
